Pandemic influenza preparedness: the critical role of the syringe

Kenneth Strauss, André van Zundert, Anders Frid, Vincenzo Costigliola, Kenneth Strauss, André van Zundert, Anders Frid, Vincenzo Costigliola

Abstract

In the face of an almost unprecedented threat of a global pandemic of influenza it is imperative that stockpiling of appropriate drugs and devices begin now. One vital device is an appropriate syringe for delivering vaccine. With the potential for millions to be infected and the vaccine supply severely stretched it is imperative that the syringe used to vaccinate waste as little vaccine as possible and thus allow for a maximum number of persons to be vaccinated. Our study tested seven leading candidate vaccine syringes for dosing accuracy, dose-capacity per vial, medication wastage and a battery of ergonomic features. One device, the Flu+trade mark syringe, proved superior to the others in all important categories, possibly due to its low dead-space volume and its dosing accuracy. The data suggest that switching to this device from any of the others tested would provide between 2 and 19% additional vaccine doses per vial if the current 10-dose vials are used. Extrapolations from this data suggest that many thousands to millions of additional persons could be vaccinated in mass campaigns. Use of a syringe of this type, and the vaccine savings that would accrue, would likely be important in reducing morbidity and mortality in the event of a pandemic of influenza.

Figures

Fig. 1
Fig. 1
A comparison of the mean weights in g of 540 doses delivered by each of the 7 devices (3780 total doses). Devices that delivers less than 0.500 g are considered to underdose (e.g. devices 3, 4 and 7), those that deliver more than 0.500 g to overdose (device 5) and those that deliver a mean closest to 0.500 g are the most accurate (e.g. devices 1 and 6). Error bars represent the 95% CI.
Fig. 2
Fig. 2
Means of residual volumes (waste) left in vials per device category. The least wasteful are devices 1 and 2 while the others are approximately twice as wasteful. Error bars indicate the 95% CI.
Fig. 3
Fig. 3
The means of dead-space volumes (n-40 per device) for the seven devices tested. Devices 1 and 2 had statistically significantly lower dead-space volumes than the other devices.
Fig. 4
Fig. 4
The syringe on the left has a plunger tip that fits into the cone-shaped end of the barrel, decreasing the amount of dead (waste) space. Compare to the conventional device on the right, where a considerable amount of dead-space (red) remains when the plunger is pushed in.

References

    1. The Writing Committee of the World Health Organization (WHO) Consultation on Human Influenza A/H5 Avian influenza A (H5N1) infection in humans. NEJM. 2005;353:1374–1385.
    1. Johnson N.P., Mueller J. Updating the accounts: global mortality of the 1918–1920 “Spanish” influenza pandemic. Bull Hist Med. 2002;76(1):105–115.
    1. Langford C. The age pattern of mortality in the 1918–19 influenza pandemic: an attempted explanation based on data for England and Wales. Med Hist. 2002;46(1):1–20.
    1. Trampuz A., Prabhu R.M., Smith T.F., Baddour L.M. Avian influenza: a new pandemic threat? Mayo Clin Proc. 2004;79:523–530. [Erratum, Mayo Clin Proc 2004;79:833]
    1. World Health Organization. WHO inter-country consultation: influenza A/H5N1 in humans in Asia, Manila, May 6–7 2005 (accessed October 12, 2005, at ).
    1. Mills C.E., Robins J.M., Lipsitch M. Transmissibility of 1918 pandemic influenza. Nature. 2004;432:904–906.
    1. Balicer R.D., Huerta M., Grotto I. Tackling the next influenza pandemic. BMJ. 2004;328:1391–1392.
    1. World Health Organization. WHO consultation on priority public health interventions before and during an influenza pandemic. April 2004 (accessed October 12, 2005, at ).
    1. European Influenza Surveillance Scheme, site .
    1. Centers for Disease Control and Prevention. Update on influenza A (H5N1) and SARS: interim recommendations for enhanced U.S. surveillance, testing, and infection controls. February 3, 2004 (accessed October 12, 2005, at ).
    1. Cox N., Subbarao K. Influenza. Lancet. 1999;354:1277–1282.
    1. Monto A.S., Gravenstein S., Elliott M., Colopy M., Schweinle J. Clinical signs and symptoms predicting influenza infection. Arch Intern Med. 2000;160:3243–3247.
    1. Seto W.H., Tsang D., Yung R.W.H., Ching T.Y., Ng T.K., Ho M. Effectiveness of precautions against droplets and contact in prevention of nosocomial transmission of severe acute respiratory syndrome (SARS) Lancet. 2003;361:1519.
    1. Moscona A. Neuraminidase inhibitors for influenza. NEJM. 2005;353:1363–1373.
    1. Hayden F.G. Pandemic influenza: is an antiviral response realistic? Pediatr Infect Dis J. 2004;23(Suppl):S262–S269.
    1. Harper SA, Fukuda K, Uyeki TM, et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2004;53:1–40.
    1. WHO site: .
    1. Hayden F.G. Perspectives on antiviral use during pandemic influenza. Philos Trans R Soc Lond B Biol Sci. 2001;356:1877–1884.
    1. Aspinall S. Comparison of BD SoloShot™ IX auto-disable syringes with conventional disposable syringes in the South African EPI programme (on file and available from BD on request).
    1. Nelson CM. Comparison of SoloShot™ IX auto destruct syringe to a disposable syringe in a national immunization campaign in Indonesia. WHO/EPI/TECHNET.98/BK.3.
    1. CDC site: .
    1. US Pharmacopeia Formulary 2004, chapter 1151, can be viewed at .

Source: PubMed

3
Se inscrever